CF PHARMTECH (02652) is currently in its IPO process. As of September 29, brokers including Futu, Phillip Securities, and Sincere Securities have collectively provided margin financing of HK$82.0086 billion for CF PHARMTECH, representing an oversubscription of more than 1343 times.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.